Tirzepatide: How Does It Work for Weight Loss? │ Pharmacology скачать в хорошем качестве

Tirzepatide: How Does It Work for Weight Loss? │ Pharmacology

Learn about tirzepatide, the promising new medication for managing obesity. This video explains its unique mechanism of action, which mimics the effects of two hormones that regulate appetite and satiety, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). We will also provide an overview of the clinical trial results that demonstrated its effectiveness in promoting weight loss and improving overall health. Disclaimer: This YouTube channel is not intended to provide diagnosis, treatment, or medical advice. The content provided in this video is for informational purposes only. This should not be considered as a substitute for healthcare professional advice. Please consult a physician or other healthcare professional regarding any medical or health-related diagnosis or treatment options. The statements about specific products are not to diagnose, treat, cure, or prevent disease. References: 1. https://www.fda.gov/news-events/press... 2. https://go.drugbank.com/drugs/DB15171 3. Farzam K, Patel P. Tirzepatide. [Updated 2024 Feb 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NB... 4. Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules. 2022;27(13):4315. Published 2022 Jul 5. doi:10.3390/molecules27134315 5. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. 6. Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM; SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023 Aug 19;402(10402):613-626. doi: 10.1016/S0140-6736(23)01200-X. Epub 2023 Jun 26. PMID: 37385275. #zepbound #weightloss #loseweight #weightlossjourney #obesity #diet #fitness #health #tirzepatide #fdaapproved #antiobesitymedication